A Two-arm Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-based Therapy

Trial Profile

A Two-arm Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Patients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-based Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Tosedostat (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms IST-CTI-MDS
  • Most Recent Events

    • 01 Mar 2017 Planned End Date changed from 1 Sep 2018 to 1 Mar 2021.
    • 01 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
    • 27 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top